IMPORTANCE Differential diagnosis of congenital vascular anomalies is challenging, and misdiagnosis is frequent. Vascular malformations are considered one of the most difficult vascular diseases to treat. A new imaging approach that visualizes anatomical features and quantitatively assesses molecular biomarkers noninvasively would aid diagnosis and monitoring of treatment response of vascular malformations.
V ascular malformations constitute a broad spectrum of angiogenic and vasculogenic disorders affecting children and adolescents. They are classified into low-flow (including venous malformation [VM] ) and fast-flow (arteriovenous malformation [AVM]) malformations. 1 Vascular malformations are always present at birth, never regress spontaneously, and can be asymptomatic for a long time. 1 However, with increasing growth, sometimes triggered by mechanical or hormonal influence, they can cause pain, extensive functional impairment, ischemia, or even cardiovascular failure. 2 The therapeutic strategy differs fundamentally based on the underlying type of malformation. Although misdiagnosis is common, consecutive false therapeutic interventions can trigger rapid disease progression. 1 Therefore, correct classification of vascular malformations according to the International Society for the Study of Vascular Anomalies scheme 3 is crucial for patient outcome. Current diagnostic imaging approaches include ultrasonography (US) and magnetic resonance imaging. Both techniques address only anatomical information but do not provide tissue-specific biomarkers. For safe lesion classification, those additional biomarkers are needed; moreover, biomarkers will enable immediate monitoring of therapy. Hence, with respect to the young patient age and necessity of repetitive monitoring, an easy-to-use and noninvasive clinical diagnostic approach is needed not only to address anatomical information but also functional biomarkers. Multispectral optoacoustic tomography (MSOT) is based on the photoacoustic effect. Absorption of pulsed, high-energy light causes thermoelastic expansion of the target tissue, inducing the transmission of US waves that can be detected and used for image reconstruction.
Owing to specific absorber properties of intrinsic biomarkers like hemoglobin, melanin, or lipids, image reconstruction can quantitatively reveal their distribution within the tissue of interest. Preclinical models of disease and the initial clinical applications of MSOT have shown the potential of the modality. [4] [5] [6] [7] [8] [9] [10] [11] With
MSOT, we present a novel noninvasive approach that provides quantitative imaging biomarkers for diagnosis and monitoring of therapy for vascular malformations.
Methods

Patients and Study Design
In this preliminary cross-sectional study, we included 12 patients ranging in age from 6 to 59 years with vascular malformations (6 with AVM and 6 with VM). Patients with AVM underwent analysis with regard to the status of embolotherapy with ethylene vinyl alcohol copolymer. Two patients with VM were investigated before and after successful sclerotherapy with polidocanol. Data were collected from April 11 to 25, 2017. This study protocol was reviewed by Ethikkommission der Westfälischen Wilhelms Universität, and all patients, or parents if the child is a minor, gave written and informed consent before study enrollment.
Technical Aspects of MSOT Imaging Device
The technical details of the clinical MSOT imaging system (MSOT Acuity Echo, iThera Medical GmbH) have been described in detail elsewhere. 4, 6 The pulse energy was attenuated to ensure adherence with American National Standards Institute limits of maximum permissible exposure. Maximum penetration depth of the laser was 3 cm. Reflection US computed tomographic mode images were generated accordingly.
MSOT Image Acquisition
Examiners experienced in US and optoacoustic scanning performed MSOT/US and were blinded to patient history and clinical data. The scanner probe was placed centered above the vascular malformation and at the equivalent region on the contralateral healthy side. The MSOT images were acquired at 6 different wavelengths ranging from 700 to 850 nm. Regions of interest were drawn in consensus by 2 examiners (M.M. and A.H.) based on the US image in the upper half of anomalous vasculature or in equivalent depth in healthy tissue. Individual contributions of oxygenated (HbO 2 ) and deoxygenated (HbR) hemoglobin were calculated from acquired data based on their spectral absorption characteristics after spectral unmixing. The HbO 2 :HbR ratio was used for comparison of AVM and VM.
Statistical Analysis
Data were analyzed from May 1 to October 31, 2017, using cLabs software (iThera Medical GmbH) and MATLAB (version R2017b; MathWorks, Inc). Statistical analysis was performed using GraphPad Prism (version 4, GraphPad Software, Inc). The 2-sided t test was used for group comparisons. Results are shown as mean (SEM). P <.05 was considered to be significant.
Results
Among the 12 patients (9 female [75%] and 3 male [25%]; mean [SD] age, 23 [18] years) included in the study, simultaneous acquisition of MSOT and US images enabled exact anatomical colocalization of vascular malformations, followed by spectral unmixing of reconstructed data for HbO 2 and HbR quantification ( Figure 1A ). The clinical hybrid MSOT/US imaging system enabled noninvasive, contrast agent-free, real-time
Key Points
Question Can multispectral optoacoustic tomography be used to distinguish between arteriovenous and venous vascular malformations by quantitative analysis of oxygenated and deoxygenated hemoglobin?
Findings In this pilot study of 12 patients with arteriovenous or venous vascular malformations, multispectral optoacoustic tomography showed significant differences between types of vascular malformations in the ratio of oxygenated to deoxygenated hemoglobin. Moreover, multispectral optoacoustic tomography enabled quantitative assessment of therapeutic response after embolization or sclerotherapy.
Meaning Multispectral optoacoustic tomography may become a promising and versatile tool for noninvasive diagnosis and monitoring of vascular malformations before and after treatment. (Figure 2A) or than in healthy tissue from 6 patients (0.94 [0.04]). Although complete embolization of AVM showed a distinct reduction in HbO 2 : HbR ratio ( Figure 2B , green label), partial embolization of AVM (n = 1) resulted in an only moderate reduction ( Figure 2B , red label). Accordingly, angiography confirmed complete treatment (eFigure 1B in the Supplement) or showed persistent arteriovenous shunting in case of partial embolization (eFigure 1C in the Supplement). Pseudocolor-coded MSOT images revealed lower HbO 2 and HbR values, depending on the therapy success between complete ( Figure 2C ) and partial ( Figure 2D ) AVM embolization.
In contrast to endovascular embolization of AVMs, VMs are treated using percutaneous sclerotherapy (eFigure 2A in the Supplement). We analyzed hemoglobin values before and after sclerotherapy in 2 patients with VM ( Figure 3A) . The mean HbO 2 :HbR ratio dropped from 1.07 before therapy to 0.82 (23% reduction) after successful sclerotherapy, equal to the ratio of the healthy tissue on the contralateral side of these patients (0.79 [0.02]) ( Figure 3A) . Magnetic resonance imaging showed successful VM treatment (eFigure 2B in the Supplement). Pseudocolor-coded MSOT images revealed a distinct difference in hemoglobin signal before and after sclerotherapy as well ( Figure 3B ). Despite the small patient number, these data suggest that MSOT enables monitoring of therapy response in patients with vascular malformations.
Discussion
Vascular malformations pose a diagnostic and therapeutic challenge owing to their heterogeneous composition and their potential for significant morbidity as early as childhood.
2 Because current techniques have various drawbacks for vascular malformation imaging, especially in children, and one may observe a high rate of misdiagnosis of up to 47% and false treatment in a usually young patient population, 1 a new tool for diagnosis and treatment monitoring would be desirable to ensure the correct diagnosis and improve patient outcome. To our knowledge, we present the first study of MSOT imaging of vascular malformations. Imaging with MSOT proved versatile in various preclinical studies as well as in first clinical applications in oncology, 4, 5, 7, 8 inflammatory bowel disease, 6 and vasculature.
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We demonstrate in a first patient cohort, to our knowledge, that MSOT/US enables differentiation of AVMs from VMs and healthy tissue via noninvasive, quantitative measurement of HbO 2 and HbR values. Multispectral optoacoustic tomography showed a significantly higher HbO 2 :HbR ratio for 
